Tanshinone IIA attenuates interleukin-17A-induced systemic sclerosis patient-derived dermal vascular smooth muscle cell activation via inhibition of the extracellular signal-regulated kinase signaling pathway. Clinics, [S. l.], v. 70, n. 4, p. 250–256, 2015. DOI: 10.6061/clinics/2015(04)06. Disponível em: https://revistas.usp.br/clinics/article/view/100991.. Acesso em: 17 jun. 2024.